Several companies on Wall Street have seen recent Seeking Alpha analyst activity, including both upgrades and downgrades.

The trove of more than 200 letters is part of a pledge of transparency from the agency, with the intention to increase public ...

On the other side, on July 7, JP Morgan analyst Chris Schott reiterated a Buy rating on Regeneron, while maintaining his $800 ...

DekaBank Deutsche Girozentrale increased its stake in Regeneron Pharmaceuticals by 4.7% this quarter, now holding 221,176 ...

This was the stock's third consecutive day of gains.

A court battle between two of the nation’s largest biotechs is testing the legal limits of how far drugmakers can go in using ...

A federal judge on Thursday declined to block the bankruptcy sale of genetic testing company 23andMe to its co-founder Anne ...

Utah families who used 23andMe's genetic testing services face unique privacy risks as the biotech company enters bankruptcy proceedings and prepares for sale t ...

Analysts have recently evaluated Regeneron Pharmaceuticals and provided 12-month price targets. The average target is $769.35, accompanied by a high estimate of $975.00 and a low estimate of $547.00.

Following updates by the CDC’s Advisory Committee on Immunization Practices, a coalition of pharmacy organizations has urged insurers to continue to cover vaccines unless there is “clear evidence of ...

Regeneron Pharmaceuticals sees strength in Dupixent, oncology gains, and major buybacks despite setbacks. Find out why REGN ...

A court battle between Regeneron and Amgen is testing the legal limits of how far drugmakers can go in using patents to ...